Wegovy
-
healthExercise Boosts Ozempic Benefits, Preserves Muscle in Obesity Study
New research at EAS 2026 shows combining semaglutide with exercise preserves muscle and enhances fat loss.
-
healthGLP-1 Drug Weight Loss Linked to Lower Disease Risk
New study finds significant weight loss from GLP-1 drugs like Ozempic reduces risk of obesity-related conditions including sleep apnea and kidney disease.
-
healthFrance Becomes First EU Country to Reimburse Weight-Loss Drugs
France will start covering costs of Wegovy and Mounjaro from June 15, a historic move making it the first EU nation to offer permanent reimbursement for GLP-1 weight-loss medications.
-
healthWeight Loss Drugs Linked to Hidden Social Stigma, Study Finds
New research reveals GLP-1 drug users face harsher judgment than those losing weight through diet and exercise.
-
healthOzempic Breath: The Unsettling Keto-Like Side Effect Patients Are Reporting
Patients taking GLP-1 drugs report 'fishy' bad breath known as Ozempic breath. Experts discuss dehydration as the likely cause.
-
healthHealth Canada Approves Second Generic Semaglutide from Apotex
Health Canada clears Apotex's generic semaglutide for type 2 diabetes, expanding access to alternatives for brand-name drugs like Ozempic.
-
healthUS Prescription Drug Spending on Track to Exceed $1 Trillion, Fueled by GLP-1s
U.S. drug spending hit $915B in 2025, set to top $1T in 2026, driven by GLP-1 weight-loss drug demand. Eli Lilly and Novo Nordisk dominate the market.
-
healthIndia's Generic Drugmakers Disrupt Weight Loss Market with Cheaper Semaglutide
Indian pharma companies launch generic semaglutide, slashing costs up to 70% and aiming to supply the global market.